Vaccines, Blood & Biologics

Interim Report on Process Validation Memo - Flublok


Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Compliance and Biologics Quality
Division of Manufacturing and Product Quality
To:                  File STN: 125285/0/13 amendment (interim report)
From:             Deborah Trout, Committee Member, MRB1, DMPQ, OCBQ, HFM-675
Through:        Carolyn Renshaw, Branch Chief, MRB1, DMPQ, OCBQ, HFM-675
Subject:          Review of interim report on Process Validation of the H3 vaccine component, submitted June 15, 2009 by Protein Sciences Corporation.
Recommendation: Outstanding issues identified below can be addressed in an Information Request, Deficiencies or Incomplete Response Letter.
Review of amendment
PSC has submitted a 2009 Process Validation interim report for the H3 vaccine component.
Comments to be conveyed to the firm:
1.     During ---(b)(4)--- of Lot --(b)(4)-- there was a failure of the --(b)(4)--  and it appears that approximately --------(b)(4)----------------------------------------------------------------------------------------------------. Please provide documentation that the Quality Unit reviewed and approved this ------(b)(4)---- step prior to its execution and associated deviation (#09-026) and investigation. In addition, please provide the executed batch records for ----(b)(4)----------------------of Lot -----(b)(4)-------.
2.     Please provide the data and associated summary report for the other strain when they become available.

Page Last Updated: 02/15/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English